MIRMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Mirum Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$82.24+2.10 (+2.62%)
Close on Oct 19, 2026
- Market cap
- $5.21B
- P/E (TTM)
- –
- Dividend yield
- –
Mirum Pharmaceuticals, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales, net | $176.24M | $159.88M | $148.93M | $133.01M | $127.79M | $111.59M | $99.43M | $90.30M | $77.76M | $68.92M | $69.55M | $47.73M | 100.0% | +37.9% |
| Livmarli | $128.72M | $113.80M | $106.39M | $92.24M | $88.16M | $73.22M | $64.09M | $59.13M | $47.23M | $42.85M | $41.49M | $38.71M | 73.0% | +46.0% |
| Bile Acid Medicines | $47.52M | $46.08M | $42.55M | $40.78M | $39.63M | $38.36M | $35.34M | $31.18M | $30.53M | $26.07M | $28.06M | $9.02M | 27.0% | +19.9% |
| License | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
| License and other revenue | – | – | $0 | $0 | $0 | $0 | – | $75.00K | $115.00K | $305.00K | $0 | $0 | – | – |
| License revenue | – | – | – | – | – | – | – | – | – | – | $0 | – | – | – |
By region
From the segment and revenue-disaggregation notes of Mirum Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.